title: Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter.
abstract: Dronedarone is an amiodarone analog but differs structurally from amiodarone in that the iodine moiety was removed and a methane-sulfonyl group was added. These modifications reduced thyroid and other end-organ adverse effects and makes dronedarone less lipophilic, shortening its half-life. Dronedarone has been shown to prevent atrial fibrillation/flutter (AF/AFl) recurrences in several multi-center trials. In addition to its rhythm control properties, dronedarone has rate control properties and slows the ventricular response during AF. Dronedarone is approved in Europe for rhythm and rate control indications. In patients with decompensated heart failure, dronedarone treatment increased mortality and cardiovascular hospitalizations. However, when dronedarone was used in elderly high risk AF/AFl patients excluding such high risk heart failure, cardiovascular hospitalizations were significantly reduced and the drug was approved in the USA for this indication in 2009 by the Food and Drug Administration. Updated guidelines suggest dronedarone as a front-line antiarrhythmic in many patients with AF/Fl but caution that the drug should not be used in patients with advanced heart failure. In addition, the recent results of the PALLAS trial suggest that dronedarone should not be used in the long-term treatment of patients with permanent AF.
authors.affiliation: Penn State Hershey Heart and Vascular Institute, Cardiac Electrophysiology Program, Hershey, PA, USA.
authors.forename: Gerald V
authors.initials: GV
authors.lastname: Naccarelli
authors.forename: Deborah L
authors.initials: DL
authors.lastname: Wolbrette
authors.forename: Vadim
authors.initials: V
authors.lastname: Levin
authors.forename: Soraya
authors.initials: S
authors.lastname: Samii
authors.forename: Javier E
authors.initials: JE
authors.lastname: Banchs
authors.forename: Erica
authors.initials: E
authors.lastname: Penny-Peterson
authors.forename: Mario D
authors.initials: MD
authors.lastname: Gonzalez
references.citation: J Cardiovasc Electrophysiol. 2006 Sep;17 Suppl 2:S17-20
references.pmid: 16939434
references.citation: J Am Coll Cardiol. 2010 Apr 13;55(15):1569-76
references.pmid: 20378073
references.citation: Am J Ther. 2013 Nov-Dec;20(6):e717-9
references.pmid: 21519214
references.citation: J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):597-605
references.pmid: 20384650
references.citation: Am Heart J. 2008 Sep;156(3):527.e1-9
references.pmid: 18760136
references.citation: Circulation. 2009 Sep 29;120(13):1174-80
references.pmid: 19752319
references.citation: Vasc Health Risk Manag. 2010 Aug 09;6:517-23
references.pmid: 20730068
references.citation: Fundam Clin Pharmacol. 2004 Feb;18(1):113-23
references.pmid: 14748763
references.citation: N Engl J Med. 2008 Jun 19;358(25):2678-87
references.pmid: 18565860
references.citation: Heart Rhythm. 2004 Nov;1(5):531-7
references.pmid: 15851214
references.citation: Clin Interv Aging. 2010 Apr 07;5:63-9
references.pmid: 20396635
references.citation: Eur Heart J. 2010 Jul;31(14):1717-21
references.pmid: 20436046
references.citation: J Cardiovasc Pharmacol. 2003 Feb;41(2):191-202
references.pmid: 12548079
references.citation: Clin Cardiol. 2010 May;33(5):270-9
references.pmid: 20513065
references.citation: Drugs Today (Barc). 2006 Feb;42(2):75-86
references.pmid: 16541184
references.citation: Br J Clin Pharmacol. 2007 Dec;64(6):785-91
references.pmid: 17662087
references.citation: N Engl J Med. 2007 Sep 6;357(10):987-99
references.pmid: 17804843
references.citation: Circulation. 2009 Aug 18;120(7):636-44
references.pmid: 19687370
references.citation: J Cardiovasc Pharmacol Ther. 2010 Dec;15(4 Suppl):15S-8S
references.pmid: 20472816
references.citation: J Pharmacol Exp Ther. 2000 Jan;292(1):415-24
references.pmid: 10604978
references.citation: J Interv Card Electrophysiol. 2011 Jun;31(1):55-60
references.pmid: 21336617
references.citation: Future Cardiol. 2005 Mar;1(2):135-44
references.pmid: 19804158
references.citation: Europace. 2011 Mar;13(3):329-45
references.pmid: 21227948
references.citation: J Cardiovasc Pharmacol. 1999 Feb;33(2):212-22
references.pmid: 10028928
references.citation: J Cardiovasc Pharmacol. 2000 Dec;36(6):802-5
references.pmid: 11117382
references.citation: Am J Cardiol. 2011 Apr 1;107(7):1019-22
references.pmid: 21296333
references.citation: Vasc Health Risk Manag. 2009;5:635-42
references.pmid: 19688104
references.citation: Eur Heart J. 2003 Aug;24(16):1481-7
references.pmid: 12919771
references.citation: N Engl J Med. 2009 Feb 12;360(7):668-78
references.pmid: 19213680
references.citation: Br J Pharmacol. 2000 Jul;130(6):1315-20
references.pmid: 10903971
references.citation: Br J Pharmacol. 2001 Jul;133(5):625-34
references.pmid: 11429385
references.citation: J Cardiovasc Pharmacol. 2000 Sep;36(3):376-83
references.pmid: 10975596
references.citation: Br J Pharmacol. 2003 Nov;140(5):996-1002
references.pmid: 14517175
references.citation: J Cardiovasc Pharmacol. 1995 Sep;26(3):453-61
references.pmid: 8583788
references.citation: Eur J Pharmacol. 1995 Jun 6;279(1):25-32
references.pmid: 7556379
references.citation: Circulation. 1999 Nov 30;100(22):2276-81
references.pmid: 10578003
references.citation: J Cardiovasc Pharmacol. 1995 Feb;25(2):252-61
references.pmid: 7752650
references.citation: J Cardiovasc Pharmacol. 1995 Oct;26(4):570-6
references.pmid: 8569217
references.citation: Heart Rhythm. 2010 Sep;7(9):1273-9
references.pmid: 20478403
references.citation: J Am Coll Cardiol. 2010 Oct 5;56(15):1216-24
references.pmid: 20883928
references.citation: J Cardiovasc Pharmacol. 2001 Oct;38(4):500-11
references.pmid: 11588520
references.citation: Eur Heart J. 2010 Oct;31(19):2369-429
references.pmid: 20802247
references.citation: N Engl J Med. 2008 Jun 19;358(25):2667-77
references.pmid: 18565859
references.citation: Circulation. 2011 Jan 4;123(1):104-23
references.pmid: 21173346
references.citation: Europace. 2011 Aug;13(8):1118-26
references.pmid: 21576129
references.citation: Am Heart J. 2010 Oct;160(4):577-82
references.pmid: 20934550
references.citation: N Engl J Med. 2002 Dec 5;347(23):1825-33
references.pmid: 12466506
references.citation: J Cardiovasc Electrophysiol. 2003 Aug;14(8):885-90
references.pmid: 12890054
references.citation: Cardiovasc Drugs Ther. 2010 Dec;24(5-6):449-58
references.pmid: 20652627
references.citation: N Engl J Med. 2009 Apr 30;360(18):1811-3
references.pmid: 19403901
references.citation: J Am Coll Cardiol. 2009 Sep 15;54(12):1089-95
references.pmid: 19744618
references.citation: J Cardiovasc Electrophysiol. 2011 Feb;22(2):201-2
references.pmid: 20550612
references.citation: J Cardiovasc Electrophysiol. 2011 Jul;22(7):770-6
references.pmid: 21288278
references.citation: J Cardiovasc Pharmacol. 2002 May;39(5):677-84
references.pmid: 11973411
references.citation: J Cardiovasc Pharmacol Ther. 2010 Dec;15(4 Suppl):24S-30S
references.pmid: 21098416